Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The MYC oncogene is a global regulator of the immune response
Stephanie C. Casey, Virginie Baylot, Dean W. Felsher
Blood (2018) Vol. 131, Iss. 18, pp. 2007-2015
Open Access | Times Cited: 204

Showing 1-25 of 204 citing articles:

The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Renumathy Dhanasekaran, Anja Deutzmann, Wadie D. Mahauad‐Fernandez, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 1, pp. 23-36
Open Access | Times Cited: 555
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Huiying Han, Atul D. Jain, Mihai I. Truica, et al.
Cancer Cell (2019) Vol. 36, Iss. 5, pp. 483-497.e15
Open Access | Times Cited: 334
MYC as a target for cancer treatment
Michael J. Duffy, Shane O’Grady, Minhong Tang, et al.
Cancer Treatment Reviews (2021) Vol. 94, pp. 102154-102154
Open Access | Times Cited: 327
MYC protein interactors in gene transcription and cancer
Corey Lourenco, Diana Resetca, Cornelia Redel, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 9, pp. 579-591
Closed Access | Times Cited: 246
WNT Signaling in Tumors: The Way to Evade Drugs and Immunity
Elena Martín‐Orozco, Ana Sanchez-Fernandez, Irene Ortiz-Parra, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 234
The MYC Oncogene Cooperates with Sterol-Regulated Element-Binding Protein to Regulate Lipogenesis Essential for Neoplastic Growth
Arvin M. Gouw, Katherine Margulis, Natalie S. Liu, et al.
Cell Metabolism (2019) Vol. 30, Iss. 3, pp. 556-572.e5
Open Access | Times Cited: 151
Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer
Elizabeth A. Bowling, Jarey H. Wang, Fade Gong, et al.
Cell (2021) Vol. 184, Iss. 2, pp. 384-403.e21
Open Access | Times Cited: 149
Genomic instability, inflammatory signaling and response to cancer immunotherapy
Mengting Chen, Renske Linstra, Marcel A.T.M. van Vugt
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1877, Iss. 1, pp. 188661-188661
Open Access | Times Cited: 119
Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy
Michael S. Hwang, Jenna VanLiere Canzoniero, Samuel Rosner, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 6, pp. e004688-e004688
Open Access | Times Cited: 85
c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment
Fangyan Gao, Xin-tong Li, Kun Xu, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 72
SHP-1 inhibition targets leukaemia stem cells to restore immunosurveillance and enhance chemosensitivity by metabolic reprogramming
Xi Xu, Yanhui Yu, Wendy Zhang, et al.
Nature Cell Biology (2024) Vol. 26, Iss. 3, pp. 464-477
Closed Access | Times Cited: 16
MYC, MYCL, and MYCN as therapeutic targets in lung cancer
Daniel Massó-Vallés, Marie‐Eve Beaulieu, Laura Soucek
Expert Opinion on Therapeutic Targets (2020) Vol. 24, Iss. 2, pp. 101-114
Closed Access | Times Cited: 98
Unlocking G-Quadruplexes as Antiviral Targets
Ardavan Abiri, Marc Lavigne, Masoud Rezaei, et al.
Pharmacological Reviews (2021) Vol. 73, Iss. 3, pp. 897-923
Open Access | Times Cited: 87
Mechanistic insights into COVID-19 by global analysis of the SARS-CoV-2 3CLpro substrate degradome
Isabel Pablos, Yoan Machado, Hugo César Ramos de Jesus, et al.
Cell Reports (2021) Vol. 37, Iss. 4, pp. 109892-109892
Open Access | Times Cited: 86
Drugging “undruggable” genes for cancer treatment: Are we making progress?
Michael J. Duffy, John Crown
International Journal of Cancer (2020) Vol. 148, Iss. 1, pp. 8-17
Open Access | Times Cited: 76
MYC as a Multifaceted Regulator of Tumor Microenvironment Leading to Metastasis
Erna Marija Meškytė, Sabiha Keskas, Yari Ciribilli
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 20, pp. 7710-7710
Open Access | Times Cited: 74
Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas
Xin Hu, Marcos R. Estecio, Runzhe Chen, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 60
Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer
Uta M. Demel, Marlitt Böger, Schayan Yousefian, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 9
Open Access | Times Cited: 49
Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments
Carine Ngo, Sophie Postel‐Vinay
Biomedicines (2022) Vol. 10, Iss. 3, pp. 650-650
Open Access | Times Cited: 40
Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways
Lavinia Spain, Alexander Coulton, Irene Lobón, et al.
Cancer Discovery (2023) Vol. 13, Iss. 6, pp. 1364-1385
Open Access | Times Cited: 38
The effects of MYC on tumor immunity and immunotherapy
Jiajin Li, Tingyu Dong, Zhenhua Wu, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 31
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation
Viktoria Marquardt, Johanna Theruvath, David Pauck, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 1, pp. e005871-e005871
Open Access | Times Cited: 28
Mechanism of Bazhen decoction in the treatment of colorectal cancer based on network pharmacology, molecular docking, and experimental validation
Shuai Lu, Xibo Sun, Zhongbao Zhou, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 26
Deciphering the role of CD47 in cancer immunotherapy
Yue Liu, Linjun Weng, Yanjin Wang, et al.
Journal of Advanced Research (2023) Vol. 63, pp. 129-158
Open Access | Times Cited: 26
Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer
Tianmei Zeng, Guang Yang, Cheng Lou, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top